MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/ju.0000000000005082

Медицинская библиотека · The Journal of urology · 2026

External Validation of the PRI-MUS Scoring System: A Secondary Analysis of the OPTIMUM Randomized Controlled Trial.

Lazarovich Alon, Guer Melis, Luger Ferdinand, Cash Hannes, Ghai Sangeet, Urdaneta-Salegui L Felipe, Pavlovich Christian P, Brito Joseph, Shore Neal D, Struck Julian P, Schostak Martin, Harland Niklas, Rodriguez-Socarrás Moisés, Brisbane Wayne G, Lughezzani Giovanni, Toledano Harry, Ouertani Mohammed Salah, Macek Petr, Fung Christopher, Tu Wendy, Gusenleitner Andreas, Günzel Karsten, Incze Peter F, George Arvin K, Pereira José G, Jansen Robert, Renzulli Joseph, Klotz Laurence, Kinnaird Adam

СтатьяВалидационное исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Micro-ultrasonography (microUS)-guided biopsy has emerged as an alternative to MRI fusion-guided biopsy for the diagnosis of prostate cancer. This study aimed to externally validate the PRI-MUS (Prostate Risk Identification using Micro-Ultrasound) scoring system for predicting clinically significant prostate cancer (csPCa) using data from the OPTIMUM trial.

MATERIALS AND

METHODS

A secondary analysis of the OPTIMUM trial was conducted to evaluate the diagnostic performance of the PRI-MUS scoring system. The analysis included patients who underwent microUS-guided prostate biopsy, with each core assigned a PRI-MUS score. The diagnostic performance of the PRI-MUS scoring system for identifying csPCa was assessed at per-core and per-lesion levels.

RESULTS

Three hundred forty-seven patients receiving microUS-guided biopsy were included. At the per-core level, 4590 biopsy cores were analyzed and assigned a PRI-MUS score. When comparing PRI-MUS 1 to 2 vs 3 to 5, the sensitivity, specificity, positive predictive value, and negative predictive value (NPV) for detecting csPCa were 72%, 74%, 37%, and 93%, respectively. The AUC was 0.78 (95% CI: 0.76 to 0.8). At the per-lesion level, 322 lesions were analyzed. When comparing PRI-MUS 1 to 2 vs 3 to 5, the corresponding sensitivity, specificity, positive predictive value, and NPV were 92%, 34%, 55%, and 83%, respectively. The AUC was 0.78 (95% CI: 0.73-0.82). Nineteen high-risk anterior lesions were biopsied, with csPCa detected in 11 (57.8%).

CONCLUSIONS

The PRI-MUS scoring system demonstrated high sensitivity and NPV for diagnosing csPCa at both the per-core and per-lesion levels, supporting its validity as a risk-stratification tool for microUS-guided biopsy.

Для цитирования: Lazarovich Alon, Guer Melis, Luger Ferdinand, Cash Hannes, Ghai Sangeet, Urdaneta-Salegui L Felipe, Pavlovich Christian P, Brito Joseph, Shore Neal D, Struck Julian P, Schostak Martin, Harland Niklas, Rodriguez-Socarrás Moisés, Brisbane Wayne G, Lughezzani Giovanni, Toledano Harry, Ouertani Mohammed Salah, Macek Petr, Fung Christopher, Tu Wendy, Gusenleitner Andreas, Günzel Karsten, Incze Peter F, George Arvin K, Pereira José G, Jansen Robert, Renzulli Joseph, Klotz Laurence, Kinnaird Adam. External Validation of the PRI-MUS Scoring System: A Secondary Analysis of the OPTIMUM Randomized Controlled Trial.. The Journal of urology. 2026. DOI: 10.1097/ju.0000000000005082.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.